cyrilzakka/clinical-trials huggingface dataset:
File Analysis of Falling Patients: Are Drugs Frequently Involved

The damage caused by patient falls is a major public health problem, due to the large and growing number of people concerned, the potentially serious consequences but also the financial cost generated by their care.

These consequences can be physical as well as psychological. Fractures and pain are the first consequences that come to mind, but many others should be mentioned: post-fall syndrome, loss of autonomy or even entering an institution, fear of falling, loss of confidence in itself.

During 2018, 285 reports of falls were counted within the Paris Saint-Joseph Hospital Group (GhPSJ). Reducing these falls is one of the institutional goals. A dedicated working group has been created to put in place preventive and corrective measures.

These falls can be caused by many factors to the patient:

1. Intrinsic:

   * History of a fall,
   * pathologies (Parkinson's or Alzheimer's disease),
   * hearing and visual disturbances,
   * urinary incontinence.
2. extrinsic:

   * Unsuitable shoes
   * unsuitable habitat,
   * slippery floors (eg bathroom).

Among the intrinsic factors, polypharmacy is also found. It has been established that certain drug classes are at risk of falling, in particular psychotropic drugs (benzodiazepines, hypnotics, anxiolytics, antidepressants, neuroleptics) which promote sedation and dizziness, hypoglycemic drugs which cause hypoglycaemia in diabetic patients on -treated or antihypertensive drugs causing hypotension.

It is now clearly established that drug adherence to treatment is poor in cities, giving rise to omissions but also sometimes to overconsumption of certain drugs, including psychotropic drugs.

Eligibility Criteria:
Inclusion Criteria:

* Major patient
* French-speaking patient
* Patient hospitalized within the Paris Saint-Joseph Hospital Group
* Patient who fell during hospitalization and for whom a fall report has been completed

Exclusion Criteria:

* Patients in the process of therapeutic limitation
* Patient under guardianship or curatorship
* Patient deprived of liberty
* Patient objecting to participation in the study
* Patient under legal protection
Pully System Exercise Role in Management of Spasticity

The goal of this clinical trial is to investigate the effect of pully system exercise in in management of spasticity in cerebral palsy children

Does pully system exercise has role in management of spasticity in cerebral palsy children ?

Participants will:

The participants assigned to the control group will receive a standard care program. This program is designed to provide basic supportive therapies without the specialized pulley system exercises

there are two groups one group will receive traditional physical therapy programme another group will receive pully system exercise

Eligibility Criteria:
Inclusion Criteria:

* Inclusion criteria
* The degree of spasticity is (1) according to Modified Ashwarth's scale
* They able to understand orders given to them.
* All children evaluated before and after the suggested period of the physical therapy program (3months).

Exclusion Criteria:

* - No fixed deformities.
* They have neither visual nor auditory problems.
* They have neither perceptual nor cognitive problems.
Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial

This study aims to investigate whether octreotide, a medication used off-label to treat chylothorax, has a direct effect on human lymphatic drainage. To study the effects of octreotide, the researchers conducted a pre-clinical experiment using human lymphatic vessels mounted in a myograph chamber and a clinical experiment in which a double-blinded, randomized, cross-over trial was conducted in 16 healthy adults. The results of the study will be used to determine the role of octreotide in the treatment of chylothorax and other lymphatic disorders.

This study aimed to investigate whether octreotide, a medication used off-label to treat chylothorax, has a direct effect on human lymphatic drainage. Chylothorax is a condition in which there is an accumulation of lymphatic fluid in the chest cavity, and the mechanism through which octreotide helps to resolve this condition is not well understood. It has been speculated that the drug may reduce lymph production, but this has not been directly demonstrated. To study the effects of octreotide on human lymphatic vessels, the investigators conducted two experiments: a pre-clinical experiment using human lymphatic vessels mounted in a myograph chamber, and a clinical experiment in which a double-blinded, randomized, cross-over trial was conducted in 16 healthy adults, assessed by using plethysmography and near-infrared fluorescence imaging. The results of the study will be used to determine the role of octreotide in the treatment of chylothorax and to clarify the mechanism through which it acts. It is important to continue researching and developing effective treatments for chylothorax, as it can be a difficult condition to manage and may cause serious complications if left untreated.

Eligibility Criteria:
Inclusion Criteria:

\* Healthy

Exclusion Criteria:

* No daily medication (except birth control), or allergies towards contrast agents.
Impact on Quality of Life in Patients Undergoing Total Gastrectomy or Proximal Gastrectomy for Adenocarcinoma of Esophagogastric Junction

The purpose of this study is to find out more about differences of the quality of life in patients undergoing total gastrectomy or proximal gastrectomy for adenocarcinoma of esophagogastric junction. To find a better reconstruction for patients who received total gastrectomy.

Overall, the incidence of stomach cancer worldwide is declining with geographical variation. However, an increase in the incidence rate of adenocarcinoma of esophagogastric junction, called cardia or AEG has been observed in recent years. AEG may represent a specific histopathological and biologic entity. In the treatment AEG there is argument over whether proximal gastractomy(PG) or total gastractomy (TG) should be done. The quality of life (QOL) of the patients following TG or PG arouses people's attention. The purpose of this study was to evaluate differences of the quality of life in patients undergoing total gastrectomy or proximal gastrectomy for adenocarcinoma of esophagogastric junction.

Eligibility Criteria:
Inclusion Criteria:

* • Pathologically confirmed gastric malignant tumor at FUSCC (biopsy may be performed at other institutions but slides must be confirmed at FUSCC, as is routine care at our institution), and the patients be assessed can achieve R0 radical dissection through total gastrectomy or proximal gastrectomy by three specialists.

  * Patients 20-75 years old
  * Normal organ function, able to tolerate surgery, no clear contraindication for surgery
  * No evidence of metastases of adjacent organs
  * be able to provide follow-up over 2 years
  * No specific treatment for gastric cancer before surgery
  * In line with the Declaration of Helsinki and the requirements of the hospital ethics committee.
  * The subjects were able to understand and comply with the trial protocol, and signed informed consent.

Exclusion Criteria:

* • AEG SiewertⅠtype patients

  * Synchronous or metachronous (less than five years) and patients with other malignancies.
  * Cirrhosis and portal hypertension
  * Associated with blood diseases
  * Serious heart/ lung and kidney dysfunction or with metabolic diseases such as diabetes, hyperthyroidism.
  * Suffering from a serious neurological disease or psychological diseases affecting the life.
Effect of Androgen Deprivation Therapy on Cardiovascular Function in Prostate Cancer

The aim of this project is to determine whether androgen deprivation therapy (ADT) decreases left ventricular function in prostate cancer patients. If found successful, this may lead to improved cardiovascular health via treatment and/or lifestyle interventions in prostate cancer populations.

Prostate Cancer is the second most common cancer among American men. Approximately 1 in 7 men will be diagnosed with prostate cancer during his lifetime. In prostate cancer patients alone, hypotestosteronemia, caused by prostate cancer treatment is associated with visceral adiposity, insulin resistance, metabolic syndrome, decreased high-density lipoprotein, increased low-density lipoprotein, increased triglycerides, loss of muscle mass, erectile disfunction, and a loss of microvascular endothelial function. Recently, several population-based studies have reported an association between androgen deprivation therapy and an increased risk of cardiovascular events, that include myocardial infarction and cardiovascular mortality. Given this link and the growing evidence that androgen-deprivation therapy adversely affects traditional risk factors, it is essential to better understand the role this type of treatment has on cardiac structure and function. As such, the manifestation of cardiovascular toxicities with prostate cancer treatment will initially be subclinical (left ventricular function changes in asymptomatic individuals) compared to clinical (including coronary symptoms or heart failure) and may develop subacutely (during treatment) or chronically.

Eligibility Criteria:
Inclusion Criteria:

* Give voluntary consent to participate in the study
* (Group 1) Diagnosed prostate cancer patient/survivor with a history of androgen deprivation therapy treatment
* (Group 2) Diagnosed prostate cancer patient/survivor with no history of androgen deprivation therapy treatment
* (Group 3) Cancer free

Exclusion Criteria:

* History of clinical cardiovascular disease (Atherosclerotic cardiovascular disease (ASCVD) defined by history of acute coronary syndromes, myocardial infarction (MI), stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemia attack (TIA), or peripheral arterial disease presumed to be of atherosclerotic origin)
* Not met the above criteria
* Unable to provide informed consent
* History of smoking (within 6 months) or current smoker
* Major signs or symptoms suggestive of cardiovascular, pulmonary, or metabolic disease. These include pain, discomfort in the chest, neck, jaw, arms or other areas that may result form ischemia; shortness of breath at rest or with mild exertion; Dizziness or syncope; Orthopnea or paroxysmal nocturnal dyspnea; ankle edema; palpitations or tachycardia; intermittent claudication; known heart murmur; unusual fatigue or shortness of breath with usual activities
Effects of SugarCut® Unripe Guava Fruit Extract on Blood Glucose Regulation

Guava (Psidium guajava) belongs to the Myrtle family. It is a tropical and subtropical fruit native to the Americas. Ripe guava fruit is sweet and delicious. It is rich in vitamins A, C and trace elements such as phosphorus, calcium and magnesium. In traditional medicine, guava fruit can be eaten raw, and the roots can treat stomach problems, abdominal pain, dysentery, and diabetes; the leaves can treat diabetes, abdominal pain, rheumatism, antipyretic, stomachache, anthelmintic, cholera, vomiting, diarrhea, enteritis and other symptoms. Guava leaf extract contains polyphenols. Studies have shown that guava leaf has antioxidant, blood sugar regulating and anti-cancer effects. Not only guava leaves, research has found that guava fruits are rich in vitamins, fiber and antioxidants, which have anti-inflammatory and anti-cancer effects. Preliminary research has found that the extract of red guava young fruit has more active ingredients - saponins and total polyphenol content, and its antioxidant capacity is also higher than that of mature guava. In vitro studies have found that guava fruit extract can increase the expression of GLUT4 gene and promote the entry of blood sugar into cells. At the same time, guava fruit extract can inhibit the formation of final glycated proteins (AGEs). The purpose of this study is to explore the effect of guava fruit extract on blood sugar regulation in humans and to evaluate its potential to be developed as a blood sugar regulation supplement.

This trial adopted a double-blind placebo-controlled parallel testing design. Subjects will be randomly assigned to the placebo group and the SugarCut® Guava Extract group, with 30 people in each group. Before the trial (week 0), subjects are required to undergo fasting blood collection and height, weight, and blood pressure examinations. Afterwards, the test samples were given to the subjects for 8 consecutive weeks, and they were reviewed for evaluation at the 4th and 8th weeks, and fasting blood collection and height, weight, and blood pressure examinations were performed.

Eligibility Criteria:
Inclusion Criteria:

1. Adults aged 20-60.
2. Fasting blood glucose level is between 100 \~ 126 mg/dL.

Exclusion Criteria:

1. Patients with renal insufficiency and kidney dialysis.
2. Cancer patients.
3. Those taking blood sugar regulation-related drugs.
4. Have a history of guava allergy
5. People suffering from mental illness
6. Pregnant and breastfeeding women
7. Long-term use of blood sugar regulating supplements
Using Mini Program for Self-management VS Conventional Pharmaceutical Care for Cancer Pain

With the existing medical system and insufficient medical resources in China, we developed a mini program. a pain management mini app can be useful and appreciated by patients and health care professionals, making it a good choice for the management of cancer pain in our country . our study want to develop and test the mini program for pain management among Chinese cancer patients in or discharged from hospital treatment.

Healthcare interventions delivered via personal mobile device have been shown to be acceptable to users, who have identified benefits such as convenience, access to personalized information, greater awareness of own health. Integrating mini program into the cancer pain care may be an effective strategy to improve cancer pain patients self-management.

To design, construct, and test the mini program in patients managing cancer pain, evaluate the total remission rate of pain and the improvement in medicine compliance to improve pain management for cancer pain patients, and assess patient acceptance of the mini program.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged 18 years or older;
* Be able to read Chinese and use a mobile phone;
* Histologically or cytologically confirmed solid tumor;
* Diagnosed chronic cancer pain
* Could understand the study process and evaluation, agreed to participate in the trial, and signed the informed consent form.

Exclusion Criteria:

* Illiterate person;
* Incompetence;
* Inability to complete the pain assessment;
* Participation in any other therapies or other study protocols that may have an impact on pain intensity, which were the main outcomes of this study;
TAP and IMS for HIPEC

It is important to decrease the postoperative pain in patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. We will compare the Transversus abdominis plane block with the Transversus abdominis plane block plus intramuscular electrical stimulation in patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.


Eligibility Criteria:
Inclusion Criteria:

-Patients who are able to do daily activity and walk independently.

Exclusion Criteria:

1. Patients with history of preoperative abdominal surgery
2. Patients who are unable to walk independently due to musculoskeletal disorder
3. Patients who are allergic to local anesthetics
4. Patients with chronic pain
5. Patients with pacemaker
6. Patients with endotracheal tube postoperatively
7. Patients with history of substance abuse
8. Pregnancy
9. Patients who are unable to communicate due to mental disorder
Post-prandial Glycemic Response to Fiber in Healthy Adults

This randomized, double-blind, comparator controlled trial evaluated the blood glucose and insulin responses in healthy adults, after consuming a high fiber or low fiber muffin top.

The fiber administered in this trial is a resistant starch type 4 derived from high-amylose maize starch. This product is high in dietary fiber (70% total dietary fiber (TDF), AOAC 2009.01 method) and can be used in a variety of bakery applications. The objective of this study was to evaluate the post-prandial blood glucose and insulin responses of healthy adults (n=28) after consuming a muffin top made with resistant starch or control muffin top, in a randomized, double-blind, crossover study. The muffin tops were matched for total weight, total carbohydrate, sugars, protein, and fat. During each 24-hour study period, subjects consumed a standard evening meal, fasted for 12 hours, and arrived at the study clinic the following morning. Serum glucose, serum insulin, and capillary glucose were measured after muffin top consumption. The subjects completed a seven day washout between treatments.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older,
* BMI 18.0-29.9 kg/m2,
* fasting glucose ≤ 6.0 mmol/L;
* if female, not of childbearing potential (e.g. taking oral contraceptives, past hysterectomy)

Exclusion Criteria:

* diagnosed metabolic or chronic diseases (e.g. type-2 diabetes);
* cancer diagnosis or treatment within 5 years;
* gastrointestinal problems;
* bowel cleansing during prior week;
* current medications to control blood glucose;
* current medications to control blood cholesterol ;
* current medications to control blood pressure;
* smoker;
* use of medical marijuana;
* alcohol or drug abuse treatment in past 12 months;
* allergy or sensitivity to study products;
* blood donation in prior 2 months;
* if female, currently pregnant, currently breastfeeding, or planning to become pregnant
Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris

To evaluate the safety and effectiveness of 3 strengths of P005672-HCl compared to placebo for the treatment of moderate to severe facial acne vulgaris.


Eligibility Criteria:
Inclusion Criteria:

* if women of child-bearing potential, have a negative urine pregnancy test
* Willing to use only a non-medicated cleanser and to refrain from use of any other acne medication, medicated cleanser, excessive sun exposure, and tanning booths for the duration of the study
* Male or female, 12-45 years of age with body weight between 52 and 88 kg
* Diagnosis of acne vulgaris with:

  20 to 50 inflammatory lesions (papules, pustules, and nodules) 30 to 100 noninflammatory lesions (open and closed comedones)
* No more than 2 nodules on the face
* Investigator's Global Assessment (IGA) score of moderate (3) to severe (4)

Exclusion Criteria:

* Dermatological condition of face or facial hair that could interfere with clinical evaluations subjects who have used the following medications (topical refers only to the facial area) will not be eligible:

Within 1 week prior to randomization:

* Medicated facial cleansers
* Topical acne treatments (other than those listed below)

Within 4 weeks prior to randomization:

* Topical retinoids
* Topical anti-inflammatories and corticosteroids
* Systemic antibiotics
* Systemic acne treatments

Within 12 weeks prior to randomization:

* Systemic retinoids
* Systemic corticosteroids
* Pseudomembranous colitis or antibiotic-associated colitis
* Hepatitis, liver damage or renal impairment
Observational Study With Mode of Action-Analysis of Cystorenal Cranberry Extract in Patients With Recurrent Urinary Tract Infections

The main focus of this observational study is to analyze the possible effects of cranberry dietary supplements on the intestinal microbiota in women with recurrent uncomplicated urinary tract infections. In a secondary analysis the possible influence of the microbiota changes on the recurrence frequency in the follow-up should be analyzed.


Eligibility Criteria:
Inclusion criteria:

• chronic recurrent urinary tract infections (≥3 infections per year or 2 infections in the last 6 months)

Exclusion Criteria:

* renal insufficiency (GFR \<60),
* anatomical or known structural causes of urinary tract infections
* regular consumption of probiotics or probiotic yogurts (at least 5x / week)
* intake of antibiotics in the last 4 weeks
* intake of Marcumar
* simultaneous participation in another study
Primary Constrained Condylar Knee Arthroplasty Without Stem Extensions: Prevalence and Risk Factors

While performing a primary TKA in consecutive patients, a constrained insert may be necessary when adequate stability and soft tissue balance are not obtained. In this retrospective study, The investigators aim to identify the prevalence and risk factors that associate with the use of a constrained insert in primary TKA.


Eligibility Criteria:
Inclusion Criteria:

* primary knee osteoarthritis
* primary total knee replacement

Exclusion Criteria:

* secondary knee osteoarthritis
* revision total knee replacement
* previous knee surgery
* post-traumatic knee
* history of previously infection
* comorbidity;rheumatoid arthritis, connective tissue disease, neuromuscular disease, lumbar spinal stenosis, neuropathy
* severe osteoporosis
Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)

This trial is conducted in Japan. To investigate the long-term efficacy as assessed by change in fat mass and safety after 48 weeks of treatment of Growth Hormone in adults with Growth Hormone Deficiency, comparing two different treatment regiments.


Eligibility Criteria:
Inclusion Criteria:

* Subjects who completed GHLiquid-1518.
* If the subject has a history of treatment for a tumor of pituitary or peripheral site, two years or more have to be passed since completion of surgery, radiotherapy or other treatment, and recurrence of the underlying disease to be excluded.
* Appropriate replacement therapy has been administered for more than 24 weeks for the treatment of other pituitary hormone deficiencies.

Exclusion Criteria:

* Subject with a history of acromegaly.
* Subject with diabetes mellitus.
* Subject suffering from malignancy.
* Several medical conditions
T1-mapping by Cardiovascular Magnetic Resonance Imaging to Assess Non-Alcoholic Fatty Liver Disease

On clinically indicated Cardiovascular Magnetic Resonance studies, native T1-times and extracellular volume of the liver will be assessed and findings correlated with established risk calculators for non-alcoholic fatty liver disease.


Eligibility Criteria:
Inclusion Criteria:

* Referred for Cardiovascular Magnetic Resonance Imaging

Exclusion Criteria:

* Non-compatible Devices
The Use of Antipsychotics in the Program of All-inclusive Care for the Elderly (PACE)

The aim of this study is to retrospectively evaluate and describe the use of antipsychotics among participants enrolled in the Program of All-inclusive Care for the Elderly (PACE), a community-based practice setting.

Much national attention has been given to assessing and reducing the use of antipsychotics among nursing home residents, yet comparatively little attention has focused on antipsychotic use among older adults receiving care in community-based settings. The primary objective of this study is to determine the prevalence of antipsychotic use among a nationally representative sample of nursing home-eligible older adults in a community-based practice setting known as Program of All-inclusive Care for the Elderly (PACE). The secondary objectives are focused on characterizing antipsychotic use within PACE and for these participants. Specifically, the investigator's secondary objectives are to describe patterns of other drugs concomitantly used with antipsychotics (e.g., benzodiazepines, opioids) and to identify clinically relevant drug-drug interactions involving antipsychotics.

Eligibility Criteria:
Inclusion Criteria:

* Participant enrolled in PACE contractually receiving pharmacy services from Tabula Rasa Healthcare CareKinesis Pharmacy (Tabula Rasa HealthCare) during the project time period (January 2017 through December 2017).

Exclusion Criteria:

* Participant with a diagnosis of bipolar disorder and/or schizophrenia, according to pharmacy records.